Bristol Myers: data to be presented at the AHA
(CercleFinance.com) - Bristol Myers Squibb announces that it will present data from its cardiovascular portfolio at the American Heart Association's (AHA) Annual Scientific Sessions, to be held 16-18 November 16 in Chicago.
Real-world and long-term extension data, including updated results from the REMS post-launch evaluation, reinforce the growing body of evidence supporting the efficacy and safety profile of Camzyos, it says.
Camzyos is approved in the US for the treatment of adults with symptomatic NYHA (New York Heart Association) class II-III hypertrophic obstructive cardiomyopathy, to improve functional capacity and symptoms.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Real-world and long-term extension data, including updated results from the REMS post-launch evaluation, reinforce the growing body of evidence supporting the efficacy and safety profile of Camzyos, it says.
Camzyos is approved in the US for the treatment of adults with symptomatic NYHA (New York Heart Association) class II-III hypertrophic obstructive cardiomyopathy, to improve functional capacity and symptoms.
Copyright (c) 2024 CercleFinance.com. All rights reserved.